English
Regional settings| Spread | 0.09 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 4.55 |
| Open | 4.46 |
| 1-Year Change | -54.86% |
| Day's Range | 4.44 - 4.52 |
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The Company's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
BRIEF: For the nine months ended 30 September 2021, Scpharmaceuticals Inc revenues was not reported. Net loss decreased 15% to $20.7M. Lower net loss reflects Research and development - Balancing decrease of 22% to $10.8M (expense), General and administrative - Balancing decrease of 9% to $6.6M (expense), Other income (expense) increase from $13K (expense) to $298K (income).
